INVA
Price:
$19.67
Market Cap:
$1.23B
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group...[Read more]
Industry
Biotechnology
IPO Date
2004-10-05
Stock Exchange
NASDAQ
Ticker
INVA
According to Innoviva, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 12.70. This represents a change of 25.21% compared to the average of 10.14 of the last 4 quarters.
The mean historical Current Ratio of Innoviva, Inc. over the last ten years is 31.89. The current 12.70 Current Ratio has changed 3.88% with respect to the historical average. Over the past ten years (40 quarters), INVA's Current Ratio was at its highest in in the March 2020 quarter at 166.87. The Current Ratio was at its lowest in in the September 2022 quarter at 2.77.
Average
31.89
Median
19.41
Minimum
9.03
Maximum
80.29
Discovering the peaks and valleys of Innoviva, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 220.23%
Maximum Annual Current Ratio = 80.29
Minimum Annual Increase = -78.82%
Minimum Annual Current Ratio = 9.03
Year | Current Ratio | Change |
---|---|---|
2023 | 9.03 | -21.08% |
2022 | 11.44 | -78.82% |
2021 | 54.02 | -3.51% |
2020 | 55.98 | -30.27% |
2019 | 80.29 | 129.92% |
2018 | 34.92 | 70.42% |
2017 | 20.49 | 18.07% |
2016 | 17.35 | 2.07% |
2015 | 17.00 | -7.26% |
2014 | 18.33 | 220.23% |
The current Current Ratio of Innoviva, Inc. (INVA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
24.83
5-year avg
42.15
10-year avg
31.89
Innoviva, Inc.’s Current Ratio is greater than eFFECTOR Therapeutics, Inc. (1.03), greater than Protalix BioTherapeutics, Inc. (1.33), greater than PDS Biotechnology Corporation (3.84), greater than aTyr Pharma, Inc. (6.07), less than Elevation Oncology, Inc. (41.10), greater than Day One Biopharmaceuticals, Inc. (4.09), greater than Mirati Therapeutics, Inc. (7.54), greater than Amylyx Pharmaceuticals, Inc. (4.66), less than Terns Pharmaceuticals, Inc. (21.02), greater than Apellis Pharmaceuticals, Inc. (5.08), greater than X4 Pharmaceuticals, Inc. (6.07), greater than Inozyme Pharma, Inc. (9.84), greater than HOOKIPA Pharma Inc. (3.86), less than Acumen Pharmaceuticals, Inc. (17.37), greater than Amicus Therapeutics, Inc. (2.75), greater than Incyte Corporation (1.92), greater than Denali Therapeutics Inc. (12.46), greater than argenx SE (8.53), greater than Harmony Biosciences Holdings, Inc. (3.13),
Company | Current Ratio | Market cap |
---|---|---|
1.03 | $211.70K | |
1.33 | $84.57M | |
3.84 | $118.19M | |
6.07 | $131.12M | |
41.10 | $35.45M | |
4.09 | $1.26B | |
7.54 | $4.12B | |
4.66 | $196.08M | |
21.02 | $706.53M | |
5.08 | $4.47B | |
6.07 | $119.23M | |
9.84 | $362.60M | |
3.86 | $158.83M | |
17.37 | $155.01M | |
2.75 | $3.26B | |
1.92 | $12.87B | |
12.46 | $4.45B | |
8.53 | $32.07B | |
3.13 | $2.22B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Innoviva, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Innoviva, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Innoviva, Inc.'s Current Ratio?
How is the Current Ratio calculated for Innoviva, Inc. (INVA)?
What is the highest Current Ratio for Innoviva, Inc. (INVA)?
What is the 3-year average Current Ratio for Innoviva, Inc. (INVA)?
What is the 5-year average Current Ratio for Innoviva, Inc. (INVA)?
How does the current Current Ratio for Innoviva, Inc. (INVA) compare to its historical average?